U7 snRNA, a Small RNA with a Big Impact in Gene Therapy
- PMID: 34139889
- DOI: 10.1089/hum.2021.047
U7 snRNA, a Small RNA with a Big Impact in Gene Therapy
Abstract
The uridine-rich 7 (U7) small nuclear RNA (snRNA) is a component of a small nuclear ribonucleoprotein (snRNP) complex. U7 snRNA naturally contains an antisense sequence that identifies histone premessenger RNAs (pre-mRNAs) and is involved in their 3' end processing. By altering this antisense sequence, researchers have turned U7 snRNA into a versatile tool for targeting pre-mRNAs and modifying splicing. Encapsulating a modified U7 snRNA into a viral vector such as adeno-associated virus (also referred as vectorized exon skipping/inclusion, or VES/VEI) enables the delivery of this highly efficacious splicing modulator into a range of cell lines, primary cells, and tissues. In addition, and in contrast to antisense oligonucleotides, viral delivery of U7 snRNA enables long-term expression of antisense sequences in the nucleus as part of a stable snRNP complex. As a result, VES/VEI has emerged as a promising therapeutic platform for treating a large variety of human diseases caused by errors in pre-mRNA splicing or its regulation. Here we provide an overview of U7 snRNA's natural function and its applications in gene therapy.
Keywords: AAV; U7 snRNA; exon inclusion; exon skipping; gene therapy; splicing modulation.
Similar articles
-
Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.Methods Mol Biol. 2011;709:179-96. doi: 10.1007/978-1-61737-982-6_11. Methods Mol Biol. 2011. PMID: 21194028
-
Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.Mol Ther. 2009 Jul;17(7):1234-40. doi: 10.1038/mt.2009.113. Epub 2009 May 19. Mol Ther. 2009. PMID: 19455105 Free PMC article.
-
Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.Biochem Biophys Res Commun. 2018 Apr 30;499(1):86-92. doi: 10.1016/j.bbrc.2018.03.102. Epub 2018 Mar 21. Biochem Biophys Res Commun. 2018. PMID: 29550480
-
U7 snRNA: A tool for gene therapy.J Gene Med. 2021 Apr;23(4):e3321. doi: 10.1002/jgm.3321. Epub 2021 Feb 23. J Gene Med. 2021. PMID: 33590603 Free PMC article. Review.
-
The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein.Cell Mol Life Sci. 2004 Oct;61(19-20):2560-70. doi: 10.1007/s00018-004-4190-0. Cell Mol Life Sci. 2004. PMID: 15526162 Review.
Cited by
-
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.J Neuromuscul Dis. 2024;11(2):499-523. doi: 10.3233/JND-230219. J Neuromuscul Dis. 2024. PMID: 38363616 Free PMC article.
-
Proof-of-concept for multiple AON delivery by a single U7snRNA vector to restore splicing defects in ABCA4.Mol Ther. 2024 Mar 6;32(3):837-851. doi: 10.1016/j.ymthe.2024.01.019. Epub 2024 Jan 18. Mol Ther. 2024. PMID: 38243599
-
RNA-Based Therapeutic Technology.Int J Mol Sci. 2023 Oct 16;24(20):15230. doi: 10.3390/ijms242015230. Int J Mol Sci. 2023. PMID: 37894911 Free PMC article. Review.
-
Promising AAV.U7snRNAs vectors targeting DMPK improve DM1 hallmarks in patient-derived cell lines.Front Cell Dev Biol. 2023 Jun 15;11:1181040. doi: 10.3389/fcell.2023.1181040. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37397246 Free PMC article.
-
A protein domain-oriented approach to expand the opportunities of therapeutic exon skipping for USH2A-associated retinitis pigmentosa.Mol Ther Nucleic Acids. 2023 May 20;32:980-994. doi: 10.1016/j.omtn.2023.05.020. eCollection 2023 Jun 13. Mol Ther Nucleic Acids. 2023. PMID: 37313440 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
